Companies

AMGN · Biotech

AMGEN INC

SEC company filings

Reported cash

USD 13,190,000,000

Sep 30, 2026

SEC filing

Cash and cash equivalents · Restricted cash and marketable securities excluded

Cash verified Nov 16, 2026

Price chart

What changed?

No verified development in tracked sources.

Upcoming catalysts

Next verified event · Expected FDA action

ABP 206 · By year-end 2026

treatment-naïve unresectable or metastatic melanoma

Announced Nov 3, 2026 · Announced window

Official announcement
Source wording

•A randomized, double-blind comparative clinical study of ABP 206 compared with OPDIVO® (nivolumab) is ongoing in patients with treatment-naïve unresectable or metastatic melanoma. The Biologics License Application (BLA) with the FDA has been submitted and accepted for review. The Company expects an FDA action on this BLA by the end of the year.

Drug pipeline

0 programs · 0 verified studies

No verified studies linked yet.

1602 unverified sponsor matches remain unlinked.

Verified timeline

0 records

No verified developments in tracked sources.